Analytic treatment interruption (ATI) is an essential component for HIV clinical trials assessing efficacy of interventions aimed at achieving HIV remission or virological control in the absence of antiretroviral or other treatments. With recent experiences of evaluating a variety of novel therapeutic interventions, including latency-reversing agents, therapeutic vaccines, and broadly neutralizing antibodies utilizing ATI, the design of treatment interruption studies has evolved towards shorter durations with more frequent monitoring and time to viral rebound as primary outcome measure. This talk will review and discuss the current practices of ATI studies on analytical approaches, design features related to the mechanism of action of the agents being evaluated, including the selection of study outcomes, ART re-initiation criteria, using historical controls vs. placebo-controlled design, as well as ethical considerations.